Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056524 · ClinicalTrials.gov registry record · Phase 3
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
A Phase 3 study, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00056524 is a Phase 3 study that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 600 participants.
The verdict
NCT00056524, a Phase 3 study, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).
Interventions
- DRUG AVP-923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2003-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056524
The ClinicalTrials.gov registry entry for NCT00056524 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVP-923 is the first listed.
NCT00056524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056524 about?
NCT00056524 is a clinical study titled "Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)". The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).
What is the current status of trial NCT00056524?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2003-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00056524?
The interventions under investigation include: AVP-923 (DRUG).
Who is sponsoring clinical trial NCT00056524?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.